HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrew Nichols Selected Research

Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)

1/2021Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial.
1/2019Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrew Nichols Research Topics

Disease

2Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
01/2021 - 01/2019
1Hereditary Angioedemas
11/2023
1Pain (Aches)
11/2023
1Needlestick Injuries (Needlestick Injury)
09/2021
1Disease Progression
01/2021
1Inflammation (Inflammations)
01/2021
1Overactive Urinary Bladder (Overactive Bladder)
07/2011
1Insulin Resistance
12/2003

Drug/Important Bio-Agent (IBA)

2edasalonexentIBA
01/2021 - 01/2019
1BradykininIBA
11/2023
1Monoclonal AntibodiesIBA
11/2023
1Proteins (Proteins, Gene)FDA Link
11/2023
1SerpinsIBA
11/2023
1Plasma KallikreinIBA
11/2023
1Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)IBA
11/2023
1Biomarkers (Surrogate Marker)IBA
01/2021
1NF-kappa B (NF-kB)IBA
01/2019
1Muscarinic AntagonistsIBA
07/2011
1Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA
07/2011
1Insulin (Novolin)FDA Link
12/2003

Therapy/Procedure

1Injections
09/2021
1Oral Administration
01/2019